Nutrigenomics in Parkinson’s disease: diversity of modulatory actions of polyphenols on epigenetic effects induced by toxins

References

• Rondón-Villarreal P, López WOC. Identification of potential natural neuroprotective molecules for Parkinson’s disease by using chemoinformatics and molecular docking. J Mol Graph Model. 2020;97:1–810.1016/j.jmgm.2020.107547.
   Web of Science ®Google Scholar
• Kidd PM. Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 2000;5:502–29.
   PubMedGoogle Scholar
• Shastry BS. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res. 2001;41:5–12. doi:10.1016/S0168-0102(01)00254-1.
   PubMed Web of Science ®Google Scholar
• Goldman SM. Environmental toxins and Parkinson’s disease. Annu Rev Pharmacol Toxicol. 2014;54:141–64. doi:10.1146/annurev-pharmtox-011613-135937.
   PubMed Web of Science ®Google Scholar
• Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci. 2009;30:475–83. doi:10.1016/j.tips.2009.06.005.
   PubMed Web of Science ®Google Scholar
• Gezer AO, Kochmanski J, VanOeveren SE, Cole-Strauss A, Kemp CJ, Patterson JR, et al. Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits. Neurobiol Dis [Internet]. Elsevier Inc. 2020;141:104947. doi:10.1016/j.nbd.2020.104947.
   PubMed Web of Science ®Google Scholar
• Baltazar MT, Dinis-Oliveira RJ, de Lourdes Bastos M, Tsatsakis AM, Duarte JA, Carvalho F. Pesticides exposure as etiological factors of Parkinson’s disease and other neurodegenerative diseases-A mechanistic approach. Toxicol Lett [Internet]. Elsevier Ireland Ltd. 2014;230:85–103. doi:10.1016/j.toxlet.2014.01.039.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Conti GO. Environment and neurodegenerative diseases: an update on miRNA role. MicroRNA. 2017 Dec 6;6(3):157–165. doi:10.2174/2211536606666170811151503.
   PubMedGoogle Scholar
• Aloizou AM, Siokas V, Sapouni EM, Sita N, Liampas I, Brotis AG, et al. Parkinson’s disease and pesticides: Are microRNAs the missing link? Sci Total Environ [Internet]. Elsevier B.V. 2020;744:140591. doi:10.1016/j.scitotenv.2020.140591.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA - J Am Med Assoc. 2020;323:548–60. doi:10.1001/jama.2019.22360.
   PubMed Web of Science ®Google Scholar
• Hornedo-Ortega R, Cerezo AB, de Pablos RM, Krisa S, Richard T, García-Parrilla MC, Troncoso AM. Phenolic compounds characteristic of the Mediterranean diet in mitigating microglia-mediated neuroinflammation. Front Cell Neurosci. 2018;12:1–20; 373. doi:10.3389/fncel.2018.00373. PMID: 30405355.
   PubMed Web of Science ®Google Scholar
• Singh A, Tripathi P, Yadawa AK, Singh S. Promising polyphenols in Parkinson’s disease therapeutics. Neurochem Res [Internet]. Springer US. 2020;45:1731–45. doi:10.1007/s11064-020-03058-3.
   PubMed Web of Science ®Google Scholar
• Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, et al. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. BioFactors. 2020: 1–8. doi:10.1002/biof.1687.
   Web of Science ®Google Scholar
• Kempuraj D, Thangavel R, Kempuraj DD, Ahmed ME, Selvakumar GP, Raikwar SP, Zaheer SA, Iyer SS, Govindarajan R, Chandrasekaran PN, Zaheer A. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma. Biofactors. 2021 Mar;47(2):190–197. doi:10.1002/biof.1687. Epub 2020 Oct 24.
   PubMed Web of Science ®Google Scholar
• Ryu YK, Park HY, Go J, Kim YH, Hwang JH, Choi DH, et al. Effects of histone acetyltransferase inhibitors on l-DOPA-induced dyskinesia in a murine model of Parkinson’s disease. J Neural Transm [Internet]. Springer Vienna. 2018;125:1319–31. doi:10.1007/s00702-018-1902-4.
   PubMed Web of Science ®Google Scholar
• Velagapudi R, Ajileye OO, Okorji U, Jain P, Aderogba MA, Olajide OA. Agathisflavone isolated from Anacardium occidentale suppresses SIRT1-mediated neuroinflammation in BV2 microglia and neurotoxicity in APPSwe-transfected SH-SY5Y cells. Phyther Res. 2018;32:1957–66. doi:10.1002/ptr.6122.
   PubMed Web of Science ®Google Scholar
• Kujawska M, Jodynis-Liebert J. Polyphenols in Parkinson’s disease: A systematic review of in vivo studies. Nutrients. 2018;10:1–34. doi:10.3390/nu10050642.
   Web of Science ®Google Scholar
• Rathore AS, Birla H, Sen SS, Zahra W, Dilnashin H, Singh R, et al. Epigenetic modulation in Parkinson’s disease and potential treatment therapies. Neurochem Res. 2021;46:1618–26. doi:10.1007/s11064-021-03334-w.
   PubMed Web of Science ®Google Scholar
• Payami H, Larsen K, Bernard S, Nutt J. Increased risk of Parkinson’s disease in parents and siblings of patients. Ann Neurol. 1994;36:659–61. doi:10.1002/ana.410360417.
   PubMed Web of Science ®Google Scholar
• Guedes L C, Mestre T, Outeiro TF, Ferreira JJ. Are genetic and idiopathic forms of Parkinson’s disease the same disease? J Neurochem. 2020;152:515–22. doi:10.1111/jnc.14902.
   PubMed Web of Science ®Google Scholar
• Domingo A, Klein C. Genetics of Parkinson disease [Internet]. 1st ed. Handbook of Clinical Neurology. Elsevier B.V.; 2018. doi:10.1016/B978-0-444-63233-3.00014-2.
   Google Scholar
• Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, et al. Genetic association between α-synuclein and idiopathic Parkinson’s disease. Am J Med Genet Part B Neuropsychiatr Genet. 2008;147:1222–30. doi:10.1002/ajmg.b.30758.
   Google Scholar
• Bai X, Jin J, Li S, Wang H, Xie A. CUB and sushi Multiple domains (CSMD1) gene polymorphisms and susceptibilities to idiopathic Parkinson’s disease in northern Chinese Han population: a case-control study. Parkinsons Dis. 2021;2021:1–10. doi:10.1155/2021/6661162.
   Web of Science ®Google Scholar
• Del Rey NLG, Quiroga-Varela A, Garbayo E, Carballo-Carbajal I, Fernández-Santiago R, Monje MHG, et al. Advances in Parkinson’s disease: 200 years later. Front Neuroanat. 2018;12:1–14. doi:10.3389/fnana.2018.00113.
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science (80-). 1997;276(5321):2045–7. doi:10.1126/science.276.5321.2045.
   PubMed Web of Science ®Google Scholar
• Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7. doi:10.1016/j.neuron.2004.11.005.
   PubMed Web of Science ®Google Scholar
• Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet. 2005;365(9457):412–5. doi:10.1016/S0140-6736(05)17829-5.
   PubMed Web of Science ®Google Scholar
• Cabezudo D, Baekelandt V, Lobbestael E. Multiple-hit hypothesis in Parkinson’s disease: LRRK2 and inflammation. Front Neurosci. 2020;14:1–8. doi:10.3389/fnins.2020.00376.
   PubMed Web of Science ®Google Scholar
• Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T, Orr-Urtreger A, et al. A “dose” effect of mutations in the GBA gene on Parkinson’s disease phenotype. Park Relat Disord [Internet]. Elsevier Ltd. 2017;36:47–51. doi:10.1016/j.parkreldis.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Balestrino R, Schapira AHV. Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications. Neuroscientist. 2018;24:540–59. doi:10.1177/1073858417748875.
   PubMed Web of Science ®Google Scholar
• Elbaz A, Ross OA, Ioannidis JPA, Soto-Ortolaza AI, Moisan F, Aasly J, et al. Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol. 2011;69:778–92. doi:10.1002/ana.22321.
   PubMed Web of Science ®Google Scholar
• Samaranch L, Lorenzo-Betancor O, Arbelo JM, Ferrer I, Lorenzo E, Irigoyen J, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain. 2010;133:1128–42. doi:10.1093/brain/awq051.
   PubMed Web of Science ®Google Scholar
• Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. [Internet]. Nature Publishing Group. 2010;28:1057–68. doi:10.1038/nbt.1685.
   PubMed Web of Science ®Google Scholar
• Lovrečić L, Maver A, Zadel M, Peterlin B. The role of epigenetics in neurodegenerative diseases. In: Kishore U, editor. Neurodegenerative disease. Intechopen.com, 2013; Chapter 14; p. 1–23. https://doi.org/10.5772/54744.
   Google Scholar
• Lin Q, Ding H, Zheng Z, Gu Z, Ma J, Chen L, et al. Promoter methylation analysis of seven clock genes in Parkinson’s disease. Neurosci Lett [Internet]. Elsevier Ireland Ltd. 2012;507:147–50. doi:10.1016/j.neulet.2011.12.007.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Saadat A. Neurodegeneration and epigenetics: a review. Neurologia (Engl Ed). 2021 Mar 9;S0213-4853(21)00034:1–7. doi:10.1016/j.nrl.2021.01.016.
   PubMedGoogle Scholar
• Labbé C, Lorenzo-betancor O, Ross OA. Epigenetic regulation in Parkinson's disease. Acta Neuropathol. 2016;132:515–530. doi:10.1007/s00401-016-1590-9.
   PubMed Web of Science ®Google Scholar
• Pavlou MAS, Pinho R, Paiva I, Outeiro TF. The yin and yang of α-synuclein-associated epigenetics in Parkinson’s disease. Brain. 2017;140:878–86. doi:10.1093/brain/aww227.
   PubMed Web of Science ®Google Scholar
• Jowaed A, Schmitt I, Kaut O, Wüllner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J Neurosci. 2010;30:6355–9. doi:10.1523/JNEUROSCI.6119-09.2010.
   PubMed Web of Science ®Google Scholar
• Pihlstrøm L, Berge V, Rengmark A, Toft M. Parkinson’s disease correlates with promoter methylation in the α-synuclein gene. Mov Disord. 2015;30:577–80. doi:10.1002/mds.26073.
   PubMed Web of Science ®Google Scholar
• Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, et al. α-synuclein sequesters Dnmt1 from the nucleus: A novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem. 2011;286:9031–7. doi:10.1074/jbc.C110.212589.
   PubMed Web of Science ®Google Scholar
• Coupland KG, Mellick GD, Silburn PA, Mather K, Armstrong NJ, Sachdev PS, et al. DNA methylation of the MAPT gene in Parkinson’s disease cohorts and modulation by vitamin E in vitro. Mov Disord. 2014;29:1606–14. doi:10.1002/mds.25784.
   PubMed Web of Science ®Google Scholar
• Su X, Chu Y, Kordower JH, Li B, Cao H, Huang L, et al. PGC-1α promoter methylation in Parkinson’s disease. PLoS One. 2015;10:1–24. doi:10.1371/journal.pone.0134087.
   Web of Science ®Google Scholar
• Kaut O, Schmitt I, Wüllner U. Genome-scale methylation analysis of Parkinson’s disease patients’ brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics. 2012;13:87–91. doi:10.1007/s10048-011-0308-3.
   PubMed Web of Science ®Google Scholar
• Masliah E, Dumaop W, Galasko D, Desplats P. Distinctive patterns of DNA methylation associated with Parkinson disease: Identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 2013;8:1030–8. doi:10.4161/epi.25865.
   PubMed Web of Science ®Google Scholar
• Park G, Tan J, Garcia G, Kang Y, Salvesen G, Zhang Z. Regulation of histone acetylation by autophagy in Parkinson disease. J Biol Chem. 2016;291:3531–40. doi:10.1074/jbc.M115.675488.
   PubMed Web of Science ®Google Scholar
• Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di Monte DA, et al. Nuclear localization of α-synuclein and its interaction with histones. Biochemistry. 2003;42(28):8465–71. doi:10.1021/bi0341152.
   PubMed Web of Science ®Google Scholar
• Mizuta I, Takafuji K, Ando Y, Satake W, Kanagawa M, Kobayashi K, et al. YY1 binds to α-synuclein 3′-flanking region SNP and stimulates antisense noncoding RNA expression. J Hum Genet. 2013;58:711–9. doi:10.1038/jhg.2013.90.
   PubMed Web of Science ®Google Scholar
• Fragkouli A, Doxakis E. miR-7 and miR-153 protect neurons against MPP+-induced cell death via upregulation of mTOR pathway. Front Cell Neurosci. 2014;8:1–14. doi:10.3389/fncel.2014.00182.
   PubMed Web of Science ®Google Scholar
• Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. A microRNA feedback circuit in midbrain dopamine neurons. Science (80-). 2007;317(5842):1220–4. doi:10.1126/science.1140481.
   PubMed Web of Science ®Google Scholar
• Kanagaraj N, Beiping H, Dheen ST, Tay SSW. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson’s disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. Neuroscience [Internet]. IBRO. 2014;272:167–79. doi:10.1016/j.neuroscience.2014.04.039.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Botta-Orfila T, Morató X, Calatayud C, Ferrer-Lorente R, Martí MJ, Fernández M, Gaig C, Raya Á, Consiglio A, Ezquerra M, Fernández-Santiago R. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiol Aging. 2018 Sep;69:283–291. doi:10.1016/j.neurobiolaging.2018.05.032.
   PubMed Web of Science ®Google Scholar
• Ghanbari M, Darweesh SKL, de Looper HWJ, van Luijn MM, Hofman A, Ikram MA, et al. Genetic variants in MicroRNAs and their binding sites are associated with the risk of Parkinson disease. Hum Mutat. 2016;37:292–300. doi:10.1002/humu.22943.
   PubMed Web of Science ®Google Scholar
• Arshad AR, Sulaiman SA, Saperi AA, Jamal R, Mohamed Ibrahim N, Abdul Murad NA. MicroRNAs and target genes as biomarkers for the diagnosis of early onset of Parkinson disease. Front Mol Neurosci. 2017;10:1–20, 352. doi:10.3389/fnmol.2017.00352. PMID: 29163029;
   PubMed Web of Science ®Google Scholar
• Sánchez-Serrano SL, Cruz SL, Lamas M. Repeated toluene exposure modifies the acetylation pattern of histones H3 and H4 in the rat brain. Neurosci Lett. 2011 Feb 11;489(3):142–7. doi:10.1016/j.neulet.2010.12.004.
   PubMed Web of Science ®Google Scholar
• Tarale P, Chakrabarti T, Sivanesan S, Naoghare P, Bafana A, Krishnamurthi K. Potential role of epigenetic mechanism in manganese induced neurotoxicity. BioMed Res Int. 2016;2016:2548792. doi:10.1155/2016/2548792.
   PubMed Web of Science ®Google Scholar
• Collotta M, Bertazzi PA, Bollati V. Epigenetics and pesticides. Toxicology [Internet]. Elsevier Ireland Ltd. 2013;307:35–41. doi:10.1016/j.tox.2013.01.017.
   PubMed Web of Science ®Google Scholar
• Song C, Kanthasamy A, Jin H, Anantharam V, Kanthasamy AG. Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. Neurotoxicology. 2011;32:586–95. doi:10.1016/j.neuro.2011.05.018.
   PubMed Web of Science ®Google Scholar
• Langston JW. The MPTP story. J Parkinsons Dis. 2017;7:S11–S19. doi:10.3233/JPD-179006.
   PubMedGoogle Scholar
• Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J Neurochem. 2008;106:486–94. doi:10.1111/j.1471-4159.2008.05417.x.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson’s disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology [Internet]. Elsevier B.V. 2015;46:101–16. doi:10.1016/j.neuro.2014.12.002.
   PubMed Web of Science ®Google Scholar
• Horst CH, Schlemmer F, de Aguiar Montenegro N, Domingues ACM, Ferreira GG, da Silva Ribeiro CY, et al. Signature of aberrantly expressed microRNAs in the striatum of rotenone-induced parkinsonian rats. Neurochem Res [Internet]. Springer US. 2018;43:2132–40. doi:10.1007/s11064-018-2638-0.
   PubMed Web of Science ®Google Scholar
• Song C, Kanthasamy A, Anantharam V, Sun F, Kanthasamy AG. Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol. 2010;77:621–32. doi:10.1124/mol.109.062174.https://doi.org/10.1124/mol.109.062174.
   PubMed Web of Science ®Google Scholar
• Kochmanski J, VanOeveren SE, Patterson JR, Bernstein AI. Developmental Dieldrin exposure alters DNA methylation at genes related to dopaminergic neuron development and Parkinson's disease in mouse midbrain. Toxicol Sci. 2019 Jun 1;169(2):593–607. doi:10.1093/toxsci/kfz069.
   PubMed Web of Science ®Google Scholar
• Mursaleen LR, Stamford JA. Drugs of abuse and Parkinson’s disease. Prog Neuro-Psychopharmacology Biol Psychiatry [Internet]. Elsevier Inc. 2016;64:209–17. doi:10.1016/j.pnpbp.2015.03.013.
   PubMed Web of Science ®Google Scholar
• Jiang W, Li J, Zhang Z, Wang H, Wang Z. Epigenetic upregulation of alpha-synuclein in the rats exposed to methamphetamine. Eur J Pharmacol. 2014;745:243–8. doi:10.1016/j.ejphar.2014.10.043.
   PubMed Web of Science ®Google Scholar
• Omonijo O, Wongprayoon P, Ladenheim B, McCoy MT, Govitrapong P, Jayanthi S, et al. Differential effects of binge methamphetamine injections on the mRNA expression of histone deacetylases (HDACs) in the rat striatum. Neurotoxicology [Internet]. Elsevier B.V. 2014;45:178–84. doi:10.1016/j.neuro.2014.10.008.
   PubMed Web of Science ®Google Scholar
• Sales NMR, Pelegrini PB, Goersch MC. Nutrigenomics: definitions and advances of this new science. J Nutr Metab. 2014;2014:1–6. Article ID 202759. doi:10.1155/2014/202759.
   Google Scholar
• Vuolo MM, Lima VS, Maróstica Junior MR. Phenolic compounds: structure, classification, and antioxidant power [Internet]. In: Bioactive compounds, Chapter 2. Elsevier Inc.; 2019. p. 33–50. doi:10.1016/B978-0-12-814774-0.00002-5.
   Google Scholar
• Eghbaliferiz S, Farhadi F, Barreto GE, Majeed M, Sahebkar A. Effects of curcumin on neurological diseases: focus on astrocytes. Pharmacol Reports [Internet]. Springer International Publishing. 2020;72:769–82. doi:10.1007/s43440-020-00112-3.
   PubMed Web of Science ®Google Scholar
• Hassan FU, Rehman MSU, Khan MS, Ali MA, Javed A, Nawaz A, et al. Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects. Front Genet. 2019;10(JUN):1–16. doi:10.3389/fgene.2019.00514.
   PubMedGoogle Scholar
• Wang Z, Yang C, Liu J, Tong BCK, Zhu Z, Malampati S, et al. A curcumin derivative activates TFEB and protects against parkinsonian neurotoxicity in vitro. Int J Mol Sci. 2020;21:1–14. 1515. doi:10.3390/ijms21041515.
   Web of Science ®Google Scholar
• Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. Curcumin modulates α-synuclein aggregation and toxicity. ACS Chem Neurosci. 2013;4:393–407. doi:10.1021/cn3001203.
   PubMed Web of Science ®Google Scholar
• Tabatabaei Mirakabad FS, Khoramgah MS, Tahmasebinia F, Darabi S, Abdi S, Abbaszadeh HA, et al. The effect of low-level laser therapy and curcumin on the expression of LC3, ATG10 and BAX/BCl2 ratio in PC12 cells induced by 6-hydroxide dopamine. J Lasers Med Sci [Internet]. 2020;11:299–304. doi:10.34172/jlms.2020.50.
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr. 2011;6:93–108. doi:10.1007/s12263-011-0222-1.
   PubMed Web of Science ®Google Scholar
• Teijido O, Cacabelos R. Pharmacoepigenomic interventions as novel potential treatments for Alzheimer’s and Parkinson’s diseases. Int J Mol Sci. 2018;19:1–36. doi:10.3390/ijms19103199.
   Web of Science ®Google Scholar
• Arora I, Sharma M, Sun LY, Tollefsbol TO. The epigenetic link between polyphenols, aging and age-related diseases. Genes (Basel). 2020;11:1–21. doi:10.3390/genes11091094.
   Web of Science ®Google Scholar
• Chiu S, Terpstra KJ, Bureau Y, Hou J, Raheb H, Cernvosky Z, et al. Liposomal-formulated curcumin [LipocurcTM] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson’s disease: implications for epigenetics-based nanotechnology-driven drug platfor. J Complement Integr Med. 2013;10:75–88. doi:10.1515/jcim-2013-0020.
   Google Scholar
• Salehi B, Venditti A, Sharifi-Rad M, Kręgiel D, Sharifi-Rad J, Durazzo A, et al. The therapeutic potential of Apigenin. Int J Mol Sci. 2019;20:1–26. doi:10.3390/ijms20061305.
   Web of Science ®Google Scholar
• Hostetler GL, Ralston RA, Schwartz SJ. Flavones: Food sources, bioavailability, metabolism, and bioactivity. Adv. Nutr. 2017;8:423–35.
   PubMed Web of Science ®Google Scholar
• Siddique YH, Naz F, Jyoti S, Afzal M. Protective effect of apigenin in transgenic Drosophila melanogaster model of Parkinson’s disease. Pharmacologyonline. 2011;3:790–5. doi:10.4081/ams.2012.e3.
   Google Scholar
• Anusha C, Sumathi T, Joseph LD. Protective role of apigenin on rotenone induced rat model of Parkinson’s disease: suppression of neuroinflammation and oxidative stress mediated apoptosis. Chem Biol Interact [Internet]. Elsevier Ireland Ltd. 2017;269:67–79. doi:10.1016/j.cbi.2017.03.016.
   PubMed Web of Science ®Google Scholar
• Chen L, Xie W, Xie W, Zhuang W, Jiang C, Liu N. Apigenin attenuates isoflurane-induced cognitive dysfunction via epigenetic regulation and neuroinflammation in aged rats. Arch Gerontol Geriatr [Internet]. Elsevier Ireland Ltd. 2017;73:29–36. doi:10.1016/j.archger.2017.07.004.
   PubMed Web of Science ®Google Scholar
• Li X, Sun S, Tong E. Experimental study on the protective effect of Puerarin to Parkinson disease. J Huazhong Univ Sci Technol – Med Sci. 2003;23:148–50. doi:10.1007/bf02859940.
   PubMedGoogle Scholar
• Zhu G, Wang X, Wu S, Li X, Li Q. Neuroprotective effects of Puerarin on 1-methyl- Parkinson ‘ s disease model in mice. Phyther Res. 2014;186(28):179–86. doi:10.1002/ptr.4975.
   Google Scholar
• Li X, Zhang J, Zhang X, Dong M. Puerarin suppresses MPP+/MPTP-induced oxidative stress through an Nrf2-dependent mechanism. Food Chem Toxicol [Internet]. Elsevier Ltd. 2020;144:111644. doi:10.1016/j.fct.2020.111644.
   PubMed Web of Science ®Google Scholar
• Xiong N, Li N, Martin E, Yu J, Li J, Liu J, et al. hVMAT2: a target of individualized medication for Parkinson’s disease. Neurotherapeutics. 2016;13:623–34.
   PubMed Web of Science ®Google Scholar
• Xiong S, Liu W, Li D, Chen X, Liu F, Yuan D, et al. Oral delivery of puerarin nanocrystals to improve brain accumulation and anti-parkinsonian efficacy. Mol Pharm. American Chemical Society. 2019;16:1444–55. doi:10.1007/s13311-016-0435-5.
   PubMed Web of Science ®Google Scholar
• dos Santos Souza C, Grangeiro MS, Lima Pereira EP, dos Santos CC, da Silva AB, Sampaio GP, et al. Agathisflavone, a flavonoid derived from Poincianella pyramidalis (Tul.), enhances neuronal population and protects against glutamate excitotoxicity. Neurotoxicology [Internet]. Elsevier B.V. 2018;65:85–97. doi:10.1016/j.neuro.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Santos CC, Muñoz P, Almeida ÁMAN, de Lima David JP, David JM, Lima Costa S, et al. The flavonoid Agathisflavone from Poincianella pyramidalis prevents aminochrome neurotoxicity. Neurotox Res. 2020;38:579–84. doi:10.1007/s12640-020-00237-6.
   PubMed Web of Science ®Google Scholar
• Calderón-Montaño JM, Burgos-Morón E, Pérez-Guerrero C, López-Lázaro M. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem. 2011 Apr;11(4):298–344. doi:10.2174/138955711795305335.
   PubMed Web of Science ®Google Scholar
• Dauncey MJ. Nutrition, the brain and cognitive decline: insights from epigenetics. Eur J Clin Nutr. Nature Publishing Group; 2014;68:1179–85. doi:10.1038/ejcn.2014.173.
   PubMed Web of Science ®Google Scholar
• Filomeni G, Graziani I, de Zio D, Dini L, Centonze D, Rotilio G, et al. Neuroprotection of kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for Parkinson’s disease. Neurobiol Aging [Internet]. Elsevier Inc. 2012;33:767–85. doi:10.1016/j.neurobiolaging.2010.05.021.
   PubMed Web of Science ®Google Scholar
• Pan X, Liu X, Zhao H, Wu B, Liu G. Antioxidant, anti-inflammatory and neuroprotective effect of kaempferol on rotenone-induced Parkinson’s disease model of rats and SH-S5Y5 cells by preventing loss of tyrosine hydroxylase. J Funct Foods. 2020;74:0–8. doi:10.1016/j.jff.2020.104140.
   Web of Science ®Google Scholar
• Berger A, Venturelli S, Kallnischkies M, Böcker A, Busch C, Weiland T, et al. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem [Internet]. Elsevier Inc. 2013;24:977–85. doi:10.1016/j.jnutbio.2012.07.001.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wu Q, Shi J, Zhou S. Regulation of SIRT3 on mitochondrial functions and oxidative stress in Parkinson’s disease. Biomed Pharmacother [Internet]. Elsevier Masson SAS. 2020;132:110928. doi:10.1016/j.biopha.2020.110928.
   PubMed Web of Science ®Google Scholar
• Sarubbo F, Moranta D, Asensio VJ, Miralles A, Esteban S. Effects of resveratrol and other polyphenols on the most common brain age-related diseases. Curr Med Chem. 2017;24(38):4245–66. doi:10.2174/0929867324666170724102743.
   PubMed Web of Science ®Google Scholar
• Arbo BD, André-Miral C, Nasre-Nasser RG, Schimith LE, Santos MG, Costa-Silva D, et al. Resveratrol derivatives as potential treatments for Alzheimer’s and Parkinson’s disease. Front Aging Neurosci. 2020;12:1–15. doi:10.3389/fnagi.2020.00103.
   PubMed Web of Science ®Google Scholar
• Lin KL, Lin KJ, Wang PW, Chuang JH, Lin HY, Der CS, et al. Resveratrol provides neuroprotective effects through modulation of mitochondrial dynamics and ERK1/2 regulated autophagy. Free Radic Res [Internet]. Taylor & Francis. 2018;52(11–12):1371–86. doi:10.1080/10715762.2018.1489128.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhu D, Jiang P, Tang X, Lang Q, Yu Q, et al. Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behav Brain Res [Internet]. Elsevier. 2019;367:10–8. doi:10.1016/j.bbr.2019.03.043.
   PubMed Web of Science ®Google Scholar
• Li W, Yang X, Song Q, Cao Z, Shi Y, Deng Y, et al. Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson’s disease. Bioorg Chem [Internet]. Elsevier. 2020;97:103707. doi:10.1016/j.bioorg.2020.103707.
   PubMed Web of Science ®Google Scholar
• Fernandes GFS, Silva GDB, Pavan AR, Chiba DE, Chin CM, Dos Santos JL. Epigenetic regulatory mechanisms induced by resveratrol. Nutrients. 2017;9:1–27. doi:10.3390/nu9111201.
   Web of Science ®Google Scholar
• Wang ZH, Zhang JL, Duan YL, Zhang QS, Li GF, Zheng DL. MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting α-synuclein expression in MPTP-induced Parkinson’s disease mouse. Biomed Pharmacother [Internet]. Elsevier Masson SAS. 2015;74:252–6. doi:10.1016/j.biopha.2015.08.025.
   PubMed Web of Science ®Google Scholar
• Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson’s disease. NeuroSignals. 2011;19:163–74. doi:10.1159/000328516.
   PubMedGoogle Scholar
• Ramírez-Garza SL, Laveriano-Santos EP, Marhuenda-Muñoz M, Storniolo CE, Tresserra-Rimbau A, Vallverdú-Queralt A, Lamuela-Raventós RM. Health effects of resveratrol: results from human intervention trials. Nutrients. 2018;10(12):1892. doi:10.3390/nu10121892.
   PubMed Web of Science ®Google Scholar
• Júnior AL G, Islam MT, Nicolau LAD, De Souza LKM, Araújo TdS, Lopes De Oliveira GA, et al. Anti-inflammatory, antinociceptive, and antioxidant properties of anacardic acid in experimental models. ACS Omega. 2020;5(31):19506–15. doi:10.1021/acsomega.0c01775.
   PubMed Web of Science ®Google Scholar
• Medeiros-Linard CFB, Andrade-da-Costa BdS, Augusto RL, Sereniki A, Trevisan MTS, Perreira RdC, de Souza FTC, et al. Anacardic acids from cashew nuts prevent behavioral changes and oxidative stress induced by rotenone in a rat model of Parkinson’s disease. Neurotox Res. 2018;34:250–62. doi:10.1007/s12640-018-9882-6.
   PubMed Web of Science ®Google Scholar
• Augusto RL, Mendonça IP, de Albuquerque Rego GN, Pereira DD, da Penha Gonçalves LV, dos Santos ML, et al. Purified anacardic acids exert multiple neuroprotective effects in pesticide model of Parkinson’s disease: in vivo and in silico analysis. IUBMB Life. 2020;72:1765–79. doi:10.1002/iub.2304.
   PubMed Web of Science ®Google Scholar
• Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today. 2009;14(19–20):942–8. doi:10.1016/j.drudis.2009.06.008.
   PubMed Web of Science ®Google Scholar
• Mazumder MK, Bhattacharjee N, Borah A. Garcinol prevents hyperhomocysteinemia and enhances bioavailability of L-DOPA by inhibiting catechol-O-methyltransferase: An in silico approach. Med Chem Res. Springer US. 2016;25:116–22. doi:10.1007/s00044-015-1472-z.
   Web of Science ®Google Scholar
• Mazumder MK, Paul R, Phukan BC, Dutta A, Chakrabarty J, Bhattacharya P, et al. Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson’s disease. Med Hypotheses [Internet]. 2018;117:54–8. doi:10.1016/j.mehy.2018.06.009.
   PubMed Web of Science ®Google Scholar
• Deb S, Phukan BC, Mazumder MK, Dutta A, Paul R, Bhattacharya P, et al. Garcinol, a multifaceted sword for the treatment of Parkinson’s disease. Neurochem Int [Internet]. Elsevier. 2019;128:50–7. doi:10.1016/j.neuint.2019.04.004.
   PubMed Web of Science ®Google Scholar